Clinical Trial Update: Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating dasatinib in patients with stage IIIB, stage IV, or recurrent non-small cell lung cancer; results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-12-24